Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A proteomics approach to understand the hypomineralisation of second primary molars (HSPM). In-vitro study.

European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry·2025

Same author

Frequency and characteristics of gnathic dense bone islands in a paediatric population residing in Chandigarh, India: a cross-sectional radiographic study.

European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry·2025

Same author

Late oral adverse effects of chemotherapy for hematological malignancies in children: A systematic review and meta-analysis of case-control studies.

Oral oncology·2024

Same author

Label-free quantitative proteomics reveals molecular correlates of altered biomechanical properties in molar incisor hypomineralization (MIH): an in vitro study.

European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry·2022

Same author

Retrospective application of the HEAR score on patients evacuated for chest pain: Assessing the utility of point-of-care troponin.

Canadian journal of rural medicine : the official journal of the Society of Rural Physicians of Canada = Journal canadien de la medecine rurale : le journal officiel de la Societe de medecine rurale du Canada·2022

Same author

Salivary parameters and their correlation with neutrophil counts in children with acute lymphoblastic leukemia.

European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry·2021

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Factor V inhibitor in thrombosis

A Kapur¹, P R Kelsey, P E Isaacs

¹Department of Medicine, Victoria Hospital, Blackpool, Lancashire, United Kingdom.

American Journal of Hematology

|April 1, 1993

Summary

A previously healthy woman developed sudden limb gangrene and liver dysfunction. This was linked to an immediate-acting inhibitor to factor V, resembling lupus anticoagulant, requiring amputation.

Area of Science:

Hematology
Vascular Medicine
Hepatology

Background:

Sudden onset limb gangrene is a rare but serious medical emergency.
Liver dysfunction can be associated with various thrombotic and hemostatic disorders.
Lupus anticoagulants are a type of antiphospholipid antibody associated with an increased risk of thrombosis.

Observation:

A 68-year-old woman presented with acute limb gangrene and concurrent liver dysfunction.
Diagnostic workup revealed an immediate-acting inhibitor targeting factor V.
The inhibitor exhibited characteristics consistent with a lupus anticoagulant.

Findings:

The patient underwent limb amputation within two weeks of symptom onset due to irreversible ischemia.
Anticoagulant activity showed a declining trend at the six-month follow-up.

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Experiment Videos

Last Updated: Jul 9, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

The case highlights a rare presentation of severe thrombotic events linked to factor V inhibition.

Implications:

This case underscores the importance of investigating thrombotic events, even in previously healthy individuals.
Early identification and management of factor V inhibitors and lupus anticoagulants are crucial for preventing severe outcomes.
Further research into the specific mechanisms and long-term management of such inhibitors is warranted.